maintaining muscle on semaglutide (GLP-1) Loss: Body Composition Changes and Findings Semaglutide results week by week:

But you knowing that you can make up for it

The risks come from the wrong patient, the wrong dose, the wrong source, or the wrong combination

Novo Nordisk and Eli Lilly, which manufacture the most prominent GLP-1s on the market, recently reached a deal with the Trump administration to reduce the price of these drugs

Long-term use over 12-24 week cycles in anecdotal reports from research users in Canada shows consistent improvements in body composition, particularly in the visceral fat compartment

Interestingly, Retatrutides nausea rate of approximately 28% at higher doses actually falls below Semaglutides 44% rate despite superior efficacy

Sources & References FDA PCAC Meeting Announcement (July 23-24, 2026) PBS: FDA to Weigh Easing Limits on Peptides Favored by RFK Jr